🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Impact of Dapagliflozin in Anemic Chronic Kidney Disease Patients

RecruitingPhase 2Ages 18 Years - anyAllMansoura University
NCT06897605 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor, primarily used in the management of type 2 diabetes mellitus. Emerging research suggests that SGLT2 inhibitors may offer additional benefits, including reducing the risk of cardiovascular events and renal complications. Post hoc analyses of previous clinical trials have shown that patients treated with SGLT2 inhibitors exhibited higher levels of hemoglobin and hematocrit compared to those in the control group. These findings suggest that dapagliflozin's ability to elevate hemoglobin levels could potentially be utilized for the treatment of anemia in patients with chronic kidney disease.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion criteria 1. Adults aged ≥ 18 years with CKD stage III or IV. 2. Patients with anemia of CKD and a hemoglobin level \< 11.5 g/dL 3. Patients are receiving erythropoiesis-stimulating agent therapy. Exclusion criteria 1. Anemia due to causes other than chronic kidney disease, such as pernicious anemia, thalassemia, sickle cell anemia, or myelodysplastic syndromes. 2. Patients with severe ketosis, diabetic coma, severe infection, perioperative complications, or severe trauma. 3. Patients with acute heart failure, acute myocardial infarction, or stroke occurring within 6 months before enrollment in the trial. 4. Patients with current malignancies or a history of malignancy within the past 2 years. 5. Diagnosed with pure red cell aplasia. 6. Patients with severe gastrointestinal bleeding. 7. Pregnant or lactating females.
💊

What it tests

  • Dapagliflozin (DAPA)
  • Erythropoiesis Stimulating Agent
📍

Where

1 site
Urology and Nephrology Center
Al Mansurah, Egypt
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy